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Measurement of care time intervals is complex, being influenced by many factors. The definition of the care interval monitored can
also bias the detection of changes in waits. The implications of using different care interval definitions to report wait times and identify
delays in care provision were examined using a retrospective chart review of 637 women with surgically treated breast cancer who
were referred to a cancer centre between September 1999 and 2000 or September 2003 and 2004. Overall waits between
detection and adjuvant treatment increased by 12 days over the two periods, but their exact location and cause(s) could not be
determined at such a low-resolution interval. At higher resolutions of care intervals, reporting the comprehensive sequence of care
events, the prolongation was mainly associated with delayed access to surgery (4 days) and delivery of adjuvant chemotherapy (4
days). The latter went unnoticed when waits were reported at intermediate (referral to adjuvant treatment) and low (detection to
adjuvant treatment) resolutions. Disease stage and type of first adjuvant treatment consistently and significantly influenced the length
of waits. Comprehensive monitoring of the entire care path is essential to effectively prioritize interventions, assess their outcomes
and optimise access to cancer care.
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Prolonged wait times in the delivery of medical care are ethically,
socially and politically contentious issues. They are important
quality of care indicators, increasingly used to direct resource
allocation and program development (Trussler, 2001; Walker and
Wilson, 2001). It has become apparent that the measurement of
care time intervals is complex and definition of the care interval
monitored may bias the detection of change in wait times (Rayson
et al, 2004). For example, in the United Kingdom, the introduction
of a ‘guaranteed’ 2-week maximum wait for urgent referrals from
general practitioners (GP) to first hospital appointment for women
with breast cancer, resulted in shorter timelines for the observed
interval (Robinson et al, 2003). However, the overall wait time
from GP referral to treatment did not improve as the shorter
timelines in the targeted care interval were offset by increases in
others (Robinson et al, 2003). Wait time assessment is further
complicated by the interplay of demographic, clinical and
epidemiologic factors, and the need to interact with a series of
health professionals working in care settings where information
flow is imperfect at best (Reed et al, 2004; Robinson et al, 2005).
The inherent complexity associated with wait times requires a
comprehensive examination of care time intervals within and
across different care events. The aims of our study were to: (1)
document wait times in breast cancer care pathways, from disease
detection to start of first adjuvant therapy; (2) examine the
implications of using different care intervals to report wait times
and identify delays in care; and (3) assesses how clinical,
demographic and treatment factors influence wait times over the
entire clinical path.
MATERIALS AND METHODS
Two cohorts of female patients were examined. Women in cohort 1
had an initial breast abnormality, detected clinically or mammo-
graphically after 1 September 1999 and were referred to one of the
two regional cancer centres (Nova Scotia Cancer Centre – NSCC or
Cape Breton Cancer Centre – CBCC) by 1 September 2000. Cohort
2 met the same eligibility criteria but had their initial breast
abnormality detected by 1 September 2003 and were referred by
1 September 2004. All patients resided in Nova Scotia and were
newly diagnosed with an invasive breast cancer for which
potentially curative surgery was undertaken. Women with in situ
(ductal or lobular) carcinoma, synchronous cancers or metastatic
disease were excluded (Figure 1).
Data were obtained from radiological, surgical and pathology
reports contained in the cancer centre patient chart, and a
database maintained by the Nova Scotia Cancer Registry and the
regional cancer centres. Dates abstracted included: (i) first clinical
or mammographic evidence of breast cancer, (ii) first pathologic
confirmation of invasive disease, (iii) last definitive surgery, (iv)
referral receipt at one of the two regional cancer centres for
consideration of adjuvant systemic or radiation therapy, (v)
patient contact by cancer centre referral or physician office, (vi)
first oncology (medical-MO or radiation-RO) consultation and
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radiation) therapy. Three levels of care interval resolution were
examined: low, intermediate and high (Figure 2). All wait times
were expressed in calendar days.
A general linear model with a stepwise selection (Po0.05) was
used to identify dominant cofactors influencing wait times at the
three levels of care interval resolution. These cofactors included:
cohort time period (Period); patient age at diagnosis (Age); area
of residence (Residence); stage of disease (Disease stage); type of
definitive surgery (Surgery type); type of first adjuvant therapy
(First Adjuvant); distance to a cancer centre derived from address
at diagnosis (Distance to cancer centre); median household income
in the area of patient residence (MHI); and mean level of education
in the area of patient residence (Education). Aggregate census data
from 1996 and 2001 were used to compute the socio-economic
factors. Days were logarithmically transformed (ln(days þ1)) to
better meet the assumption of data normality (Armitage and Berry,
1994). Geometric mean elapsed times and their 95% confidence
intervals were estimated after correcting for all cofactors that
significantly influenced wait times (i.e., the fully adjusted model
including first-order interactions with Period).
The simultaneous correlations among all wait times and
cofactors were summarised using Principal components analysis
(Manly, 1986; Legendre and Legendre, 1998; Smith, 2002).
Principal components analysis is a multivariate method that
decomposes the correlations or co-variances between all variables
into subsets that best capture the total variability in the data. These
subsets are new composite variables (‘principal axes’) holding
information from all variables of interest but largely reflecting
those variables with the greatest variability and therefore the
strongest influence. Dominant patterns in a data set can usually be
summarised by the first two ‘principal axes’, with the primary axis
(PC1) accounting for the greatest proportion of the variation in the
data set; the second axis (PC2) accounting for the next largest
variation, etc. The graphical presentation of these composite axes
(i.e., ‘ordination’) has the feature that patients sharing similar
characteristics will tend to cluster. Correlations among patients
were determined from their profiles (demography, type of surgical
and adjuvant treatment, etc.) and the wait they have experienced in
each care interval. Patients with ‘common’ profiles or experiencing
‘average timelines’ will usually cluster near the centre of the
ordination whereas patients with atypical profiles or experiencing
atypical wait times (either very long or very short timelines) will be
found towards the extremes of the ordination.
RESULTS
A total of 637 women met the inclusion criteria and contributed to
this study (Figure 1). Between the two cohorts, the proportion of
patients residing in one region increased in the later period (Cape
Breton increased from 14.3 to 23.4%; P¼0.013; see Table 1). As
well, the proportion of patients undergoing breast conservation
relative to modified radical mastectomies increased over the time
periods (from 40.4 to 48.3%; P¼0.057).
Cohort 1
(1999–2000)
Cohort 2
(2003–2004)
752 774 New diagnoses of breast cancer in Nova Scotia
313 343
67
Disease stage unknown or 
metastatic at diagnosis 
26 In situ disease
10 Diagnosed out of province
12 Synchronous invasive disease
4 Male breast cancer
461
342
58
36
16
17
4
Cases not referred to a cancer centre 
within dates specified in inclusion criteria
409
295 Cases retained for analysis
Figure 1 Case selection and exclusion criteria for two patient cohorts:
cohort 1 (1999–2000) and cohort 2 (2003–2004). Some cases may be
excluded for more than one reason.
Care events taking place mainly outside the cancer centre
Detection
Oncology 
consultation 
(MO/RO)
Biopsy Surgery Referral Patient contact
Detection Referral
Intermediate resolution
High resolution
Detection First adjuvant 
First adjuvant 
First adjuvant 
Low resolution
Care events taking place mainly inside the cancer centre
Figure 2 Selected levels of resolution of care intervals for breast cancer care: (1) low-resolution (long composite/overall interval embracing all events –
Detection–First Adjuvant); (2) intermediate-resolution (mid-size composite intervals embracing some, but not all care events – Detection–Referral;
Referral–First Adjuvant); and (3) high-resolution (small intervals embracing single/isolated care events – Detection–Biospy; Biopsy–Surgery; Surgery–
Referral; Referral–Patient Contact; Patient Contact–Oncology Consultation; Oncology Consultation–First Adjuvant).
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Detection–First Adjuvant), a significant prolongation in waits was
observed between cohorts, increasing from 90 days to 102 days
(i.e., a Period effect, Po0.001; Figure 3). Women living at greater
distances from a cancer centre experienced an additional increase
in wait times during the latter period (P¼0.028; Figure 3). As this
interval is composed of many subintervals, it was not possible to
precisely identify where along the path the prolongation(s)
occurred or if single or multiple events were prolonged.
Overall, for both cohorts combined, the average wait for this
interval was 96 days, with 75% of the patients starting adjuvant
therapy within 122 days of disease detection (Rayson et al,i n
press; Figure 3). Patients receiving radiotherapy as first adjuvant
treatment experienced significantly longer care intervals relative to
patients receiving chemotherapy or hormonal therapy (123 vs 88
or 88 days, respectively; Po0.001). Those diagnosed with stage I
disease experienced significantly longer waits than did patients
diagnosed with stage II or stage III disease (100 vs 97 or 85 days,
respectively; P¼0.009). Finally, those undergoing modified radical
mastectomy experienced an additional 6 days before the start of
first adjuvant therapy relative to patients undergoing breast
conservation surgery (P¼0.044).
When wait times were expressed at an intermediate resolution
(i.e., Detection–Referral; Referral–First Adjuvant; Figure 4),
significant prolongations were mostly associated with processes
taking place outside the cancer centres (i.e., Detection–Referral).
Women diagnosed in the later period waited an average of 8
additional days before referral to a cancer centre was received
(Po0.001).
Overall, for both cohorts combined, patients waited an average
of 58 days between disease detection to cancer centre referral and
35 days between cancer centre referral to the start of first adjuvant
Table 1 Characteristics of selected cases: Cohort 1 (1999–2000) and
Cohort 2 (2003–2004)
Number of women (%)
Characteristics Cohort 1 Cohort 2
Residence
Central Nova Scotia 163 (47.7) 124 (42.0)
Cape Breton Island (CB) 49 (14.3) 69 (23.4)
Elsewhere in Nova Scotia (Other) 130 (38.0) 102 (34.6)
v
2 (P-value): 8.6 (0.013)
Age at diagnosis
p49 95 (27.8) 74 (25.1)
50–69 176 (51.5) 157 (53.2)
X70 71 (20.8) 64 (21.7)
v
2 (P-value): 0.59 (0.744)
Disease stage
I 152 (44.4) 124 (42.0)
II 147 (43.0) 129 (43.7)
III 43 (12.6) 42 (14.2)
v
2 (P-value): 0.59 (0.755)
Type of surgery
Lumpectomy 131 (40.4) 127 (48.3)
Mastectomy 193 (59.6) 136 (51.7)
v
2 (P-value): 3.6 (0.057)
First adjuvant therapy
Hormonal therapy 63 (21.2) 64 (26.1)
Chemotherapy 157 (52.9) 116 (47.4)
Radiotherapy 77 (25.9) 65 (26.5)
v
2 (P-value): 2.2 (0.331)
w
2 tests of differences between cohorts and associated P-values are presented.
Period P < 0.001
2000:  90 (86.6 – 94.3) [221]
2004: 102 (98.0 – 106.4) [225]
Disease stage P = 0.009 
I:  100 (94.8 – 104.5) [178]
II:   97 (92.4 – 100.9) [210]
III:  85 (77.7 – 92.1) [58]
Type of surgery P = 0.044 
Lump: 93 (88.3 – 97.2) [213]
Mast:  99 (95.1 – 103.9) [233]
First adjuvant P < 0.001 
Hormonal:  88 ( 81.9 – 93.6) [99]
Chemo:      88 ( 84.6 – 92.2) [231]
Radiation:  123 (114.9 – 131.6) [116]
Period: distance to cancer centre
P = 0.028  [446]
2000 Shorter time with >distance
2004 Longer time with >distance
96 Detection First adjuvant 
Figure 3 Wait times at low resolution. Shown in circles between intervals, are unadjusted geometric mean number of elapsed days. Below each interval
are shown the covariates found to have a significant effect. Adjusted geometric mean number of days with 95% confidence intervals are shown in parenthesis
and the sample size appears in square brackets. Period main effects are shown for every interval and interaction terms are represented by a colon. Period
2000 refers to cohort 1; Period 2004 refers to cohort 2.
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longer ‘Detection-Referral’ waits than those with stages II or III (66
days vs 53/43 days, respectively; Po0.001) as did patients living
closer to a cancer centre (P¼0.005). Patients from Cape Breton
initiated treatment sooner than patients in Central Nova Scotia or
elsewhere in the province (29 vs 38 or 35 days, respectively;
Po0.001); and patients receiving hormonal therapy initiated
treatment sooner than patients receiving chemotherapy or
radiation therapy (25 vs 33 or 54 days, respectively; Po0.001).
This interval (i.e., Referral–First Adjuvant) was marked by a
change in the influence of distance to a cancer centre, disease stage
and surgery type between periods: patients living further from a
cancer centre (P¼0.001) or diagnosed with stage II or III disease
(P¼0.025) or undergoing modified radical mastectomy
(P¼0.037) waited longer to initiate adjuvant therapy in the later
period.
When wait times were expressed at a high resolution (Figure 5),
three major care events showed prolongation over time. Two of
these prolongations were associated with processes taking place
mostly outside the cancer centres (Biopsy–Surgery, 4 additional
days; Surgery–Referral, 2 additional days) and one was associated
with processes taking place mostly within the cancer centres
(Oncology Consultation–First Adjuvant, 4 additional days).
Factors influencing delays between the two cohorts could not be
identified for the care intervals of Biopsy–Surgery and Surgery–
Referral. However, the significantly prolonged wait time observed
between cohorts for Oncology Consultation–First Adjuvant was
associated with adjuvant hormonal or chemotherapy treatment
modality (hormonal treatment: 2 vs 0 days; chemotherapy: 14 vs 9
days) and more advanced stage (stage II: 12 vs 7 days; stage III: 23
vs 9 days).
The dominant patterns of co-associations among all wait times
and cofactors are summarised in Figure 6. The first axis largely
describes factors that are disease-dependent, and possibly intrinsic
to the practice of a health care institution (PC1), whereas the
second axis describes factors that are extrinsic to a health care
institution (PC2). More specifically, PC1 suggests that patients
undergoing mastectomy or receiving hormonal treatment as first
Detection Referral First adjuvant 
Period P < 0.001 
2000: 53 (49.5 – 55.9) [266]
2004: 61 (57.3 – 64.5) [253]
Disease stage P < 0.001 
I:   66 (61.6 – 69.8) [222]
II:  53 (49.5 – 56.3) [233]
III: 43 (38.1 – 48.1) [64]
Education P = 0.043 [519]
Shorter time with >education
Distance to cancer centre 
P = 0.005 [519]
Shorter time with >distance
Period P = 0.371
2000: 33 (30.8 – 35.5) [261]
2004: 38 (35.0 – 40.4) [225]
Residence P < 0.001 
Central: 38 (34.6 – 42.6) [217]
CB:        29 (25.4 – 32.1) [ 96]
Other:    35 (31.8 – 38.8) [173]
First adjuvant P < 0.001
Hormonal:  25 (22.0 – 27.4) [104]
Chemo:     33 (30.6 – 35.0) [257]
Radiation:  54 (48.9 – 60.4) [125]
Period : Disease stage P = 0.025 
2000 Stage I:  34 (30.3 – 37.4) [99]
2004 Stage I:  33 (29.6 – 36.6) [94]
2000 Stage II: 33 (30.0 – 36.5) [127]
2004 Stage II: 43 (38.2 – 47.5) [96]
2000 Stage III: 32 (26.6 – 37.5) [35]
2004 Stage III: 36 (30.5 – 43.4) [35]
Period: Distance to cancer centre
P = 0.001 [486]
2000 Shorter time with >distance
2004 Longer time with >distance
Period: Type of surgery P = 0.037 
2000 Lump I:  33 (29.9 – 37.4) [113]
2004 Lump I:  34 (30.7 – 37.9) [112]
2000 Mast: 33 (29.9 – 35.8) [148]
2004 Mast: 41 (36.9 – 45.3) [113]
58 35
Figure 4 Wait times at intermediate resolution. Shown in circles between intervals are unadjusted geometric mean number of elapsed days. Below each
interval are shown the covariates found to have a significant effect. Adjusted geometric mean number of days with 95% confidence intervals are shown in
parenthesis and the sample size appears in square brackets. Period main effects are shown for every interval and interaction terms are represented by a
colon. Period 2000 refers to cohort 1; Period 2004 refers to cohort 2.
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Biopsy–Surgery, Oncology Consultation–First Adjuvant, Refer-
ral–First Adjuvant and Detection–First Adjuvant. Conversely,
patients undergoing lumpectomy or receiving radiation as first
adjuvant therapy experienced longer waits. PC2 suggests that
patients served by the NSCC, living closer to a cancer centre, with
higher MHI and education levels tended to experience shorter
times between Detection and Biopsy, Surgery and Referral, and
Detection and Referral. Conversely, patients served by the CBCC,
living at greater distance from a cancer centre, with lower MHI and
education levels experienced longer waits.
DISCUSSION
Increases in waits over time were detected at all care interval
resolutions. However, high resolution intervals provided the most
precise determination of the location and magnitude of these
increases. Intermediate resolution intervals also helped to
determine whether increases in wait over time occurred within
or outside the cancer centres but could not detect changes within
a given interval. For example, the highly significant increase in
time between oncology consultation and start of first adjuvant
treatment detected at high resolution went unnoticed when
intervals were resolved at an intermediate resolution (i.e.,
Referral–First Adjuvant). This was likely a result of an intentional
compensation of one interval for delays in another (i.e., a triage
effect similar to the UK case detailed in the Introduction). The
lowest resolution of care intervals provided minimal information
as to location or magnitude of effect, masking all useful
information for targeted interventions.
Patients in the later period experienced an additional 12 days
in overall care timelines largely owing to delayed access to surgery
and delivery of adjuvant therapy. These points of care represent
targets for discussion and potential intervention. Other key factors
consistently influencing wait times were disease stage and type of
first adjuvant treatment. Patients with early stage disease
experienced longer waits in nearly all intervals, which may reflect
the prioritization of patients with more advanced disease at
diagnosis. Patients receiving radiotherapy as first adjuvant
treatment also experienced longer wait times in nearly all intervals,
which could partly reflect time lags associated with the planning of
radiotherapy and/or prolonged referral-medical oncology consult.
In our practice, the decision to proceed to radiation may be
delayed until a final decision is made with regard to whether or not
chemotherapy will be recommended. Therefore, wait times to a
medical oncology consultation may adversely affect timelines of
radiation therapy administration (see Rayson et al, in press). Less
consistently influencing wait times were surgery type, location of
patient residence and proximity of residence to a cancer centre.
Education and income levels were important factors influencing
wait times within a period but not between periods.
A significant increase in wait over time suggests the presence of
a systemic deterioration of health care provision for women with
early stage breast cancer in Nova Scotia. Significant changes over
time in the influence of disease, treatment or epidemiologic
variables on wait time may be early warning indicators of
impending changes in health care provision. That is, they may
Period P < 0.001
2000:  8 (7.1 – 9.0) [261]
2004: 12 (10.8 – 14.0) [220]
Residence P = 0.05
Central: 11 (9.5 – 12.4) [215]
CB:          8 (6.5 – 9.8) [94]
Other:      9 (8.1 – 10.9) [172]
Disease stage P = 0.015
I:    9  (7.8 – 10.6)  [193]
II:   9  (8.1 – 10.7) [219]
III : 13 (10.6 – 17.1)  [69]
Type of surgery P = 0.018
Lump: 11 (9.7 – 13.0) [223]
Mast:     9 (7.5 – 9.8) [258]
First adjuvant P < 0.001 
Hormonal:   1 (0.69 – 1.50) [99]
Chemo:     11 ( 9.6 – 12.3) [257]
Radiation: 31 (26.0 – 37.9) [125]
Period: Disease stage P = 0.014
2000 Stage I:  9 (6.9 – 10.5) [100]
2004 Stage I: 10 (7.9 – 12.1) [93]
2000 Stage II:   7 (6.1 – 8.8) [125]
2004 Stage II: 12 (10.1 – 15.0) [94]
2000 Stage III:   9 (6.1 – 12.0) [36]
2004 Stage III: 23 (16.2 – 31.4) [33]
Period: First adjuvant P = 0.010 
2000 Hormonal: 0 (0.11 – 0.94) [47]
2004 Hormonal: 2 (1.4 – 2.9) [52]
2000 Chemo:  9 (  7.3 – 10.2) [149]
2004 Chemo: 14 (11.4 – 17.1) [108]
2000 Radiation: 31 (24.4 – 40.4) [65]
2004 Radiation: 31 (24.3 – 40.5) [60]
Period P = 0.333
2000: 5 (4.1 – 5.5) [310]
2004: 5 (4.5 – 6.2) [257]
Residence P = 0.008
Central: 5 (3.9 – 6.4) [256]
CB:        8 (5.9 – 9.8) [108]
Other:    4 (3.1 – 5.0) [203]
Period: Residence P = 0.001
2000 Central:  4 (3.2 – 5.6) [147]
2004 Central:  6 (4.4 – 8.1) [109]
2000 CB: 10 (7.1 – 14.7) [46]
2004 CB:   5 (3.8 – 7.2) [62]
2000 Other: 3 (2.6 – 4.6) [117]
2004 Other: 5 (3.3 – 6.1) [86]
Period: Disease stage P = 0.049 
2000 Stage I:  5 (3.6 – 5.7) [134]
2004 Stage I:  7 (5.5 – 8.8) [109]
2000 Stage II: 5 (3.9 – 6.1) [138]
2004 Stage II: 5 (3.5 – 5.8) [110]
2000 Stage III: 5 (3.1 – 7.0) [38]
2004 Stage III: 4 (2.2 – 5.5) [38]
Period: Type of surgery P = 0.018
2000 Lump I:  5 (3.9 – 6.2) [127]
2004 Lump I:  4 (3.2 – 5.2) [124]
2000 Mast: 5 (3.8 – 5.6) [183]
2004 Mast: 7 (5.2 – 8.1) [133]
Period P = 0.132
2000:  9 (7.7 – 9.6) [311]
2004:  8 (6.8 – 8.7) [257]
Residence P < 0.001
Central: 12 (9.8 – 14.1) [256]
CB:          3 (2.4 – 3.9) [109]
Other:      8 (7.0 – 9.9) [203]
Disease stage P = 0.026
I:    8 (6.6 – 8.5)  [243]
II:   9 (8.1 – 10.4) [251]
III : 7 (5.7 – 8.9)  [74]
Type of surgery P < 0.001
Lump:  7 (5.8 – 7.6) [250]
Mast: 10 (8.6 – 10.7) [318]
Period: Residence P  < 0.001
2000 Central: 14 (11.5 – 17.2) [147]
2004 Central: 10 (  7.5 – 11.9) [109]
2000 CB: 2 (1.3 – 3.0) [47]
2004 CB: 5 (3.6 – 6.1) [62]
2000 Other: 9 (7.3 – 11.1) [117]
2004 Other: 8 (6.0 – 9.4) [86]
Detection
Oncology
consultation
(MO/RO)
Biopsy Surgery Referral Patient contact First adjuvant  13 20 16 8 5 10
Period P = 0.581
2000: 13 (11.3 – 14.7) [261]
2004: 14 (11.9 – 15.6) [243]
Disease stage P < 0.001 
I:   17 (15.0 – 19.7) [231]
II:  11 ( 9.5 – 12.8)  [214]
III :  9 ( 6.8 – 12.1)  [59]
Education P = 0.003 [504]
Shorter time with >education
Period: Residence P = 0.02
2000 Central: 15 (12.1 – 17.7)  [129]
2004 Central: 12 ( 9.4 – 14.3) [106]
2000 CB: 10 ( 6.7 – 13.9) [37]
2004 CB: 14 (10.3 – 18.0) [59]
2000 Other: 13 (10.1 – 15.8) [95]
2004 Other: 17 (13.4 – 21.5) [78]
Period P = 0.005
2000: 17 (14.8 – 18.4) [289]
2004: 21 (18.4 – 23.2) [243]
Distance to cancer centre 
P < 0.001 [532]
Shorter time with >distance
Type of surgery P = 0.046
Lump: 20 (17.8 – 22.6) [237]
Mast:   17 (15.4 – 19.0) [295]
Period P = 0.034
2000: 14 (13.1 – 15.7) [313]
2004: 16 (14.9 – 18.1) [239]
Residence P = 0.013
Central: 13 (11.3 – 15.2) [ 247]
CB:        17 (14.3 – 19.5) [102]
Other:    17 (15.3 – 19.9) [203]
Age at diagnosis P < 0.001
49:      13 (11.5 –14.9) [135]
50 – 69: 15 (13.7 – 16.4) [295] 
70:      19 (16.4 –21.5) [122] 
Disease stage P = 0.001
I:    16 (14.5 – 17.6) [239]
II:   16 ( 14.5 – 17.7)  [238]
III : 11 ( 9.5 – 13.5)  [75]
Distance to cancer centre 
P<0.032 [552]
Shorter time with >distance
Figure 5 Wait times at high resolution. Shown in circles between intervals, are unadjusted geometric mean number of elapsed days. Below each interval
are shown the covariates found to have a significant effect. Adjusted geometric mean number of days with 95% confidence intervals are shown in parenthesis
and the sample size appears in square brackets. Period main effects are shown for every interval and interaction terms are represented by a colon. Period
2000 refers to cohort 1; Period 2004 refers to cohort 2.
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path that represents a target for proactive intervention. For
example, wait time between patient contact and first oncology
consultation did not vary between cohorts (period effect
P¼0.333). However, patients diagnosed with stage I disease or
served by the NSCC experienced longer times to consultation in
the later period, perhaps reflecting the development of a bottleneck
in accessing medical oncologists.
Prospective and consistent monitoring of wait time intervals
at high resolutions may be an effective method to detect delays in
access to care and allow a more directed prioritisation of
interventions and evaluation of their outcomes. Developing high-
resolution monitoring programs might seem costly and logistically
challenging, but many cancer agencies currently monitor wait
times to varying degrees (Reed et al, 2004; Wait Time Alliance for
Timely Access to Health Care, 2005; Canadian Institute for Health
Information, 2006; Savage, 2006). Refining these pre-existing
operational programs to a higher level of care path resolution
may increase the potential for effective intervention and be more
cost-effective.
This study examined the care path associated with one disease.
However, system compensation between disease sites may be
occurring. To obtain a more complete understanding of wait times
for cancer care, an integrated, multidisciplinary approach crossing
disease sites and service boundaries is required. For example, the
recent indication for adjuvant chemotherapy in high-risk Non
Small Cell Lung Carcinoma following curative surgery may
influence a number of breast cancer care segments in some cancer
centres depending on the structure of care delivery and resources.
As indications for adjuvant therapy and options for palliative
treatments continue to expand, we suggest that high-resolution
assessment of care time intervals across all common cancers will
become even more important if programmatic and resource
interventions are to be targeted appropriately.
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Figure 6 Ordination showing the inter-relationships between wait times (’) and their cofactors ( ). Longer arrows indicate stronger influences.
Arrows pointing in the same directions indicate strong co-associations. Arrows of care intervals point in the direction of increasing wait times. Arrows for
categorical cofactors point in the direction of the highest classification order as described in Table 1. PC1 and PC2 accounted for 18 and 14% of the total
variance in the data, respectively. Patients (cases) appear as points. Patients clustering in the second quadrant were generally from Cape Breton, living further
from a cancer centre, with lower education and income levels, undergoing lumpectomy and receiving radiation therapy as first adjuvant treatment and
experiencing prolonged elapsed times in most care intervals with the exception of Referral–Patient Contact. Most wait times were oriented (increasing) in
the same direction as the period effect, highlighting the general (although not necessarily statistically significant) prolongation of wait times in most care
intervals.
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